Antiretroviral Therapy

Sporotrichosis, a fungal infection being transmitted by feral cats, is a potential threat on the CDC’s radar.

DENVER — Long-acting ART was shown to be safe and effective in a study conducted in sub-Saharan Africa — an “essential first step” in demonstrating its potential use to treat HIV on the continent, an expert said.

DENVER — People with HIV who have challenges adhering to a daily oral regimen should be offered long-acting formulations of ART, study findings suggest.

DENVER — Phase 2 study data showed that a once-weekly oral regimen of an investigational two-drug HIV treatment was well tolerated among patients with HIV and allowed them to maintain viral suppression.

DENVER — The International Antiviral Society-USA (IAS-USA) has updated its HIV treatment guidelines to endorse the off-label use of long-acting injectable ART in patients with HIV viremia.

Results from an ongoing trial showed that long-acting injectable ART for HIV is effective for people who struggle to consistently take a daily course of medication, the NIH and ViiV Healthcare announced.

Rates of cause-specific mortality among people with HIV on ART declined between 1996 and 2020, with the largest reductions being in rates of AIDS-related mortality, researchers found.

PHILADELPHIA — Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk for CVD, according to new data from the REPRIEVE trial.

Using physiologically based pharmacokinetic modeling combined with observed clinical data, researchers determined that obesity can lead to reduced exposure and response to antiretroviral drugs.

Long-acting injectable cabotegravir/rilpivirine paired with extensive support services for nonsuppressed people with HIV with adherence barriers would likely increase viral suppression and improve survival, researchers found.